Evidence mapPaperPMID 41973270Full record

ReviewCurrent cardiology reports2026

Interrelationships Between Key Cardiovascular Risk Factors, Chronic Kidney Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease.

Emir Muzurović, Ksenija Zečević, Dimitri P Mikhailidis

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Emir MuzurovićDepartment of Internal Medicine, Endocrinology Section, Clinical Center of Montenegro, Podgorica, Montenegro. dremir@t-com.me.
Ksenija ZečevićDepartment of Internal Medicine, Endocrinology Section, Clinical Center of Montenegro, Podgorica, Montenegro.
Dimitri P MikhailidisDepartment of Surgical Biotechnology, Division of Surgery and Interventional Science, UCL and Department of Clinical Biochemistry, University College (UCL) London Medical School, Royal Free Hospital Campus, UCL Medical School, UCL, Pond Street, London, NW3 2QG, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewFive modifiable risk factors (RFs) - systolic blood pressure (SBP), body mass index (BMI), diabetes, non-high-density lipoprotein cholesterol (non-HDL-C), and smoking - were proposed as major determinants of the global burden of cardiovascular disease (CVD). This narrative review considers the interconnections among these RFs and their combined influence on disease development, progression, and longevity. We also consider the relationship between these factors and chronic kidney disease (CKD) and metabolic dysfunction-associated steatotic liver disease (MASLD). RECENT

findingsOver the past three decades, the global prevalence and burden of CVD, CKD, and MASLD has risen substantially. These chronic conditions are leading causes of reduced life expectancy and increased disability-adjusted life years (DALYs). They share common underlying mechanisms, particularly insulin resistance and chronic inflammation, and frequently coexist, with each condition accelerating the progression and complications of the others. Evidence from studies and meta-analyses demonstrates that the five traditional RFs significantly contribute to disease onset and progression, while effective risk-factor management can delay disease progression and improve both quality of life and survival. Lifestyle interventions and emerging pharmacological therapies can favorably modify these RFs and reduce the overall burden of CVD, CKD, and MASLD. An integrated approach to managing metabolic dysfunction is essential, although it remains challenging, as improvement in one condition may adversely affect another. RFs should not just be considered individually.

Indexed as

Cardiovascular DiseasesFatty LiverNon-alcoholic Fatty Liver DiseaseRenal Insufficiency, ChronicBody Mass IndexDisease ProgressionHeart Disease Risk FactorsHumansMetabolic SyndromePrevalenceRisk FactorsCardiovascular risk factorsChronic kidney diseaseDiabetes mellitus type 2Metabolic dysfunction-associated steatotic liver diseaseMetabolic syndrome

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.